# Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma

> **NCT05759312** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 20 (estimated)

## Conditions studied

- Ovarian Clear Cell Carcinoma

## Interventions

- **DRUG:** Zimberelimab
- **DRUG:** Metformin Hydrochloride

## Key facts

- **NCT ID:** NCT05759312
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-03
- **Primary completion:** 2025-02
- **Final completion:** 2025-02
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2023-03-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05759312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05759312, "Zimberelimab Plus Metformin for Recurrent Ovarian Clear Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05759312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*